Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities

Decera Clinical Education Oncology Podcast · Apr 15, 2026 · 31m

Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices.

Presenters:

Nadia Harbeck, MD

Breast Cancer Director

Department of OB&GYN and Comprehensive Cancer Center Munich

LMU University Hospital

Munich, Germany

Francois-Clement Bidard, MD, PhD

Breast Medical Oncology

Institut Curie & University of Versailles

Paris, France

Link to full program:

https://bit.ly/4cFd0Xj

Get access to all our new podcasts by…